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RESEARCH
Rare and low frequency genomic variants 
impacting neuronal functions modify 
the Dup7q11.23 phenotype
Farah Qaiser1,2, Yue Yin2, Carolyn B. Mervis3, Colleen A. Morris4, Bonita P. Klein‑Tasman5, Elaine Tam6, 
Lucy R. Osborne1,6 and Ryan K. C. Yuen1,2* 
Abstract 
Background: 7q11.23 duplication (Dup7) is one of the most frequent recurrent copy number variants (CNVs) in 
individuals with autism spectrum disorder (ASD), but based on gold‑standard assessments, only 19% of Dup7 carriers 
have ASD, suggesting that additional genetic factors are necessary to manifest the ASD phenotype. To assess the con‑
tribution of additional genetic variants to the Dup7 phenotype, we conducted whole‑genome sequencing analysis of 
20 Dup7 carriers: nine with ASD (Dup7‑ASD) and 11 without ASD (Dup7‑non‑ASD).
Results: We identified three rare variants of potential clinical relevance for ASD: a 1q21.1 microdeletion (Dup7‑non‑
ASD) and two deletions which disrupted IMMP2L (one Dup7‑ASD, one Dup7‑non‑ASD). There were no significant dif‑
ferences in gene‑set or pathway variant burden between the Dup7‑ASD and Dup7‑non‑ASD groups. However, overall 
intellectual ability negatively correlated with the number of rare loss‑of‑function variants present in nervous system 
development and membrane component pathways, and adaptive behaviour standard scores negatively correlated 
with the number of low‑frequency likely‑damaging missense variants found in genes expressed in the prenatal 
human brain. ASD severity positively correlated with the number of low frequency loss‑of‑function variants impacting 
genes expressed at low levels in the brain, and genes with a low level of intolerance.
Conclusions: Our study suggests that in the presence of the same pathogenic Dup7 variant, rare and low frequency 
genetic variants act additively to contribute to components of the overall Dup7 phenotype.
Keywords: 7q11.23 duplication syndrome, Autism spectrum disorder, Phenotypic variability, Single nucleotide 
variant, Copy number variant, Whole genome sequencing
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Background
Duplication of the 7q11.23 region (referred to as Dup7) 
[1] results in a rare complex neurodevelopmental disor-
der (MIM 609757) with an estimated prevalence of one in 
7500–20,000 individuals [2, 3]. Individuals with a Dup7 
copy number variant (CNV) have common Dup7 char-
acteristics including distinctive craniofacial features (i.e., 
macrocephaly, brachycephaly, broad forehead, straight 
eyebrows, deep-set eyes, a broad nasal tip with low inser-
tion of the columella, a short philtrum, thin vermillion of 
the upper lip, minor ear anomalies and facial asymme-
try). Structural brain anomalies include ventriculomeg-
aly, decreased white matter volume, and cerebellar vermis 
hypoplasia, while abnormal neurological findings include 
hypotonia, abnormalities of gait and station, adventitious 
movements, seizure disorder, and developmental coordi-
nation disorder [4–6]. In addition, common Dup7 char-
acteristics include aortic dilation, developmental delay, 
low-average intellectual ability, speech sound disorder, 
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social anxiety disorder, selective mutism, and autism 
spectrum disorder (ASD) [4–6].
Over the past decade, studies have pointed to a strong 
association between Dup7 and ASD, with Dup7 identi-
fied as one of the ten most frequently (0.2%) recurring 
CNVs found in children with ASD [2, 7–12]. We previ-
ously conducted the first systematic characterization of 
ASD symptomatology in a group of 63 children (aged 
4–17 years) with Dup7, finding evidence for an elevated 
risk of ASD, as 33% of the cohort screened positive for 
possible ASD [3]. In our subsequent study of an overlap-
ping sample, 19% of the participants with Dup7 received 
a clinical diagnosis of ASD following gold-standard 
assessments [4, 5, 9]. Interestingly, in the reciprocal 
deletion of the 7q11.23 region, which causes Williams-
Beuren syndrome (WBS, MIM 194050), the prevalence 
of ASD symptomatology and diagnosis is also consider-
ably higher than in the general population [13, 14].
Dup7 is a significant ASD risk factor, but despite having 
the same shared CNV, most individuals with Dup7 do not 
meet the criteria for ASD diagnosis using a gold-standard 
diagnostic approach [9]. This phenomenon of incomplete 
penetrance and phenotypic variability has been observed 
in a number of neuropsychiatric phenotypes, including 
those associated with syndromic or multigenic CNVs, 
and single genes [15–19]. For example, the 22q11 dele-
tion syndrome (22q11DS) is characterized by significant 
differences in the penetrance of congenital heart defects, 
schizophrenia and ASD. A recent study found that 20% of 
22q11DS carriers with ASD had a second variant within 
the mGluR5 network in contrast to only 2% of 22q11DS 
carriers who did not have ASD, suggesting that a ‘second 
hit’ significantly contributes to ASD risk in 22q11DS [17]. 
Similarly, Pizzo et  al. [16] assessed the contribution of 
rare variants in individuals with different primary patho-
genic variants, finding that the number of additional hits 
correlated with the variability and severity of the overall 
clinical phenotype. Such studies add support to the ‘mul-
tiple hit’ model, which proposes that syndromic CNVs 
exhibit incomplete penetrance and variable expressivity 
for ASD and instead require additional genetic factors—
often referred to as ‘second hits’ or modifiers—in order 
for individuals to present with ASD [16, 18, 20].
However, there are challenges associated with the 
multiple hit model, as not all studies have successfully 
identified additional genetic factors to explain pheno-
typic variability. For example, Masson et al. [21] carried 
out whole-exome sequencing (WES) and chromosomal 
microarray analysis (CMA) for six individuals with WBS-
ASD but did not identify any secondary variants which 
could explain the presence of ASD in these individuals. 
Such studies highlight the need to utilize methods that 
allow for a thorough examination of the different variants 
present in an individual’s genetic background, which 
will allow for a better understanding of incomplete pen-
etrance and phenotypic variability.
In this study, we carry out the first whole-genome 
sequencing (WGS) analysis to examine the role of rare 
(< 1%) and low-frequency (< 5%) variants in the develop-
ment of ASD in Dup7 carriers. WGS has the potential to 
identify nearly all forms of genetic variation, including 
single nucleotide variants (SNVs), indels and CNVs. Pre-
vious studies have demonstrated the advantages of WGS 
for ASD molecular diagnosis, such as a higher molecular 
diagnostic rate and the ability to detect non-coding vari-
ants [22–26]. Since prior studies [15–19, 27] have suc-
cessfully identified rare secondary variants in individuals 
with ASD, we carried out rare variant analysis in this 
Dup7 cohort to identify potential modifiers. By examin-
ing the rare and low frequency damaging variants present 
in each Dup7 carrier’s genetic background, we aimed 
to better understand how additional variants modulate 
neuropsychiatric phenotypes in individuals carrying the 
same primary pathogenic variant.
Results
Whole‑genome sequencing (WGS) and chromosomal 
microarray analysis (CMA)
Each participant carried a classic Dup7 CNV. For 79.2% 
of the participants, we were able to determine if the CNV 
was de novo (17 participants; 71%) or inherited (two par-
ticipants; 4%; one from each group), and the CNV par-
ent-of-origin. The pattern of CNV parent-of-origin was 
similar for the two groups: four maternal, five paternal 
for Dup7-ASD; six maternal, four paternal for Dup7-
non-ASD (Fisher exact test, P = 0.656). In terms of clini-
cal characteristics, there were no significant differences 
in sex, age at assessment, or General Conceptual Abil-
ity (GCA; similar to IQ) standard scores (SS) between 
the Dup7-ASD and the Dup7-non-ASD groups (Fig.  1; 
Additional file  1: Table  S3). However, as expected, the 
Dup7-ASD group had a significantly higher ASD symp-
tom calibrated severity score (CSS) than the Dup7-non-
ASD group (P = 8.43 × 10–7) (Fig.  1; Additional file  1: 
Table S3). The Dup7-ASD group also had a significantly 
lower Broad Independence standard score (BroadInd SS, 
P = 0.010), which is a measure of overall adaptive behav-
ior ability, than the Dup7-non-ASD group (Fig. 1; Addi-
tional file 1: Table S3).
We sequenced the genomes from 24 Dup7 carri-
ers, with an average of 43.9 × coverage across all sam-
ples (Additional file  1: Table  S2). One individual had a 
greater than expected number of rare CNVs and was thus 
excluded from downstream analyses (Additional file  1: 
Figure S1, Table S2). When compared to reference sam-
ples from the 1000 Genomes project, ancestry analysis 
Page 3 of 11Qaiser et al. Orphanet J Rare Dis            (2021) 16:6  
found that most of the Dup7 carriers were either Euro-
pean (n = 18, 75%) or American (n = 3, 12.5%) (Addi-
tional file 1: Figure S2, Methods). Of the remaining three 
Dup7 carriers, one clustered with the South Asian ances-
try group, while the other two did not cluster with any 
group. These three individuals were excluded for poten-
tial confounding effects in downstream analyses. Lastly, 
kinship analysis confirmed that the participants within 
the cohort were unrelated (Additional file 1: Figure S3).
Overall, a total of nine participants with Dup7-ASD 
and 11 with Dup7-non-ASD were used in downstream 
analyses, where we detected an average of 4,685,522 
indels and SNVs, and 661 CNVs per genome (Addi-
tional file 1: Table S2). Examining rare variants only, we 
detected an average of 185 indels and SNVs, and 35.4 
CNVs impacting coding regions per genome (Additional 
file 1: Figure S1; Table S3). For the 20 participants used 
in downstream analyses, there were no significant dif-
ferences in the distributions of Dup7 CNV size between 
the Dup7-ASD (Mean: 1,658,333 bp, SD: 175,468 bp) and 
Dup7-non-ASD (1,564,455  bp, SD: 33,721  bp) groups 
(Mann–Whitney U test, z = 0.80, P = 0.424) (Additional 
file 1: Table S4).
Clinically relevant rare variant analysis
We identified three rare variants of potential clinical 
relevance to ASD: a pathogenic 1q21.1 microdeletion 
in an individual with Dup7-non-ASD and two differ-
ent rare deletions which disrupt IMMP2L at the 7q31.1 
locus (one Dup7-ASD, one Dup7-non-ASD) (Table  1). 
These three rare CNVs impact both the coding and non-
coding regions of the genome. The latter two CNVs were 
of different sizes, and both were classified as VUS. We 
did not identify any SNVs or indels which met clinical 
Fig. 1 Comparison of demographic and clinical characteristics between the Dup7‑ASD and Dup7‑non‑ASD groups. Boxplots comparing the 
following clinical characteristics between the Dup7‑ASD and the Dup7‑non‑ASD groups: a age (P = 0.713); b General Conceptual Ability standard 
score (GCA; similar to IQ) from the Differential Ability Scales‑II (P = 0.319); c Calibrated severity score from the ADOS‑2 (P = 7.40 × 10–7); and d Broad 
Independence standard score from the Scales of Independent Behavior‑Revised (P = 0.01). Statistically significant differences are marked with an 
asterisk, where P values less than 0.05 are marked with a single asterisk, P values less than 0.01 are marked with two asterisks, and P values less than 
0.001 are marked with three asterisks
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significance per American College of Medical Genetics 
and Genomics (ACMG) guidelines. Overall, there was no 
significant difference in rare variant findings between the 
Dup7-ASD group and the Dup7-non-ASD group.
Burden analysis of genomic variants
To assess the correlation between phenotypic measures 
and the burden of variants (either rare or low frequency) 
in participants with Dup7, we performed regression 
analysis and found that GCA SSs were negatively corre-
lated with the burden of (1) low frequency LoF variants 
(P = 0.012), (2) a combination of low frequency LoF and 
missense variants (P = 0.022), and (3) rare non-Dup7 
CNVs (P = 0.016) (Additional file 1: Table S5). There was 
no significant correlation between the burden of genomic 
variants and the remaining phenotypic measures (i.e. 
Dup7-ASD vs. Dup7-non-ASD, BroadInd SS, CSS) 
(Additional file 1: Table S5).
Correlation of function and pathway with phenotypic 
outcomes
To assess the contribution of likely damaging rare and 
low frequency variants to the overall Dup7 neuropsy-
chiatric phenotype, we conducted regression modelling 
to identify correlations between phenotypic outcomes 
and different burden variables in gene-sets (ASD-risk, 
Neuroset) or pathways (GO, KEGG) (Table  2). Upon 
examining individual variant types, we found that 
BroadInd SSs (where higher scores indicate better 
adaptive behaviour skills) were negatively correlated 
with likely damaging low frequency missense variants 
enriched in genes expressed in the prenatal human 
brain (P = 0.003; FDR = 0.078, Fig.  2a). We observed 
Table 1 Rare clinically relevant variants identified in the Dup7 cohort
CNV copy number variant, DEL deletion
* Each CNV listed here is found in a different participant
Group* Gene(s) Variant type Variant Chromosome coordinates 
(GRCh37/hg19)
Variant category
Dup7‑non‑ASD ACP6, BCL9, CHD1L, FMO5, GJA5, GJA8, 
GPR89B, NBPF10, NBPF11, NBPF12, 
NBPF20, NBPF8, PRKAB2
CNV DEL Chr1:146,303,401‑ 147,891,400
Size: 1,588,000 bp
Pathogenic
Dup7‑non‑ASD IMMP2L, LRRN3 CNV DEL Chr7:110,347,001‑ 110,883,800
Size: 536,800 bp
Variant of uncertain significance
Dup7‑ASD IMMP2L CNV DEL Chr7:111,120,394–111,351,748
Size: 231,355 bp
Variant of uncertain significance
Table 2 Biological processes significantly enriched among  genes carrying a  higher number of  rare or  low frequency 
variants in Dup7 carriers
CSS calibrated severity score (from ADOS-2), GCA General Conceptual Ability standard score (from DAS-II), GO gene ontology, LoF loss of function, PC1 principal 
component 1, BroadInd SS SIB-R Broad Independence standard score. Percentages in parentheses refer to variant frequency
Outcome 
phenotype
Variable Pathway 
category
Pathway/
function
Number 
of genes 
in pathway
Number 
of observed 
variants
B (coefficient) P value FDR
BroadInd SS Likely damaging 
missense vari‑
ants (5%)
Neuroset Brain
Pre‑natal (PC1 
bottom 33%)
3038 451 − 2.75 3.10 × 10–3 0.078
CSS LoF variants (5%) Neuroset Brain low/absent 
expression
4601 145 0.574 3.19 × 10–3 0.078
LoF variants (5%) Neuroset Genic intolerance, 
very low (Q1)
4153 164 0.662 5.87 × 10–3 0.078
GCA LoF variants (1%) Neuroset Nervous System 
Development
1874 8 − 25.2 2.28 × 10–3 0.074
LoF variants (1%) GO Side of mem‑
brane 
[GO:0098552]
426 3 − 43.0 3.61 × 10–4 0.148
LoF variants (1%) GO External Side 
of Plasma 
Membrane 
[GO:0009897]
232 3 − 43.0 3.61 × 10–4 0.148
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a negative correlation between GCAs (where higher 
scores indicate higher intellectual ability) and rare likely 
damaging LoF variants enriched in nervous system 
development (P = 0.002; FDR = 0.074, Fig. 3a), and two 
membrane component GO pathways (P = 3.61 × 10–4; 
FDR = 0.148, Fig. 3B). Lastly, CSSs (where higher scores 
are associated with higher levels of ASD symptoms) 
were positively correlated with low frequency LoF vari-
ants enriched in genes expressed in low levels in the 
brain (P = 0.003; FDR = 0.078, Fig. 4) and in genes with 
a very low level of intolerance (P = 0.006; FDR = 0.078, 
Fig. 4).
Similarly, to assess the contribution of non-coding 
variants which cause cryptic splicing to the overall Dup7 
neuropsychiatric phenotype, we repeated the above 
regression modelling analyses, with the inclusion of vari-
ants with a high likelihood of disrupting splicing in the 
LoF SNV burden variable (1%, 5%) (Additional file  1: 
Table S6). We detected a total of 29 rare and 46 low fre-
quency variants with a high likelihood of disrupting 
Fig. 2 Volcano plot of relationship between BroadInd SS and likely damaging variants present in neuroset pathways. Volcano plot of likely 
damaging missense variants (5% frequency level) expressed in neuroset pathways for the BroadInd SS outcome variable. Labelled functions met a P 
value cut‑off of at most 0.05 and have a false discovery rate (FDR) of ≤ 0.15
Fig. 3 Volcano plot of relationship between GCA and likely damaging variants in GO and neuroset pathways. Volcano plot of rare LoF variants (1% 
frequency level) expression in neuroset (a) and GO (b) pathways for the GCA outcome variable. Labelled functions met a P value cut‑off of at most 
0.05 and have a false discovery rate (FDR) of ≤ 0.15. GCA DAS‑II General Conceptual Ability standard score, GO gene ontology, LoF loss of function
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splicing, as predicted by SpliceAI [28]. We found a signif-
icant correlation in two of the aforementioned pathways. 
Specifically, there were significant positive correlations 
between CSSs and (i) both rare (P = 0.004; FDR = 0.091) 
and low frequency (P = 0.002; FDR = 0.036) LoF variants 
enriched in genes expressed in low levels in the brain, 
and (ii) low frequency LoF variants impacting genes with 
a very low level of intolerance (P = 0.011; FDR = 0.105).
Discussion
In this study, we present the first systematic WGS analy-
sis of participants with Dup7, with and without ASD, 
to explore the role of additional genetic variants in the 
development of ASD in 7q11.23 duplication syndrome. 
A comparison of the genetic background between the 
individuals with Dup7-ASD (n = 9) and the individuals 
with Dup7-non-ASD (n = 11) found no significant dif-
ferences in variant findings between the two groups, but 
instead showed that in the presence of the same primary 
pathogenic Dup7 variant, there are additional variants 
involved, which likely act additively to contribute to the 
overall intellectual ability and adaptive behavior compo-
nents of the Dup7 phenotype. These results suggest that 
in addition to the primary pathogenic variants, rare and 
low frequency variants present in the genetic background 
modulate the clinical variability seen in neurodevelop-
mental disorders (NDDs) such as Dup7.
We identified one pathogenic 1q21.1 deletion and 
two VUS CNVs of interest impacting IMMP2L in this 
Dup7 cohort, representing 15% of the samples investi-
gated. Haploinsufficiency at the 1q21.1 locus is associ-
ated with various phenotypes, and past studies point to 
1q21.1 duplications being more strongly associated with 
ASD or ASD-like features than deletions [29, 30]. This 
is consistent with the finding of a 1q21.1 deletion in an 
individual with Dup7-non-ASD in our cohort. We also 
identified two deletions which disrupted IMMP2L and 
were found in both Dup7-ASD and Dup7-non-ASD par-
ticipants. Of note, IMMP2L encodes the second subunit 
of the inner mitochondrial membrane peptidase complex 
and has previously been reported as a potential candi-
date gene associated with ASD, Tourette syndrome and 
other NDDs [31–33]. These CNV findings add to the 
available evidence regarding IMMP2L’s potential role in 
neurodevelopment, but its contribution to ASD remains 
uncertain given that a CNV disrupting solely IMMP2L 
was identified in a Dup7-non-ASD individual who had an 
ADOS-2 CSS of 1 (the lowest possible score).
There were no significant differences in Dup7 size, 
gene-set or pathway variant burden between the Dup7-
ASD and Dup7-non-ASD groups. We did identify sta-
tistically significant correlations between continuous 
phenotypic measures (CSS, GCA and BroadInd SS) and 
rare or low frequency variants in pathways impacting 
neuronal functions. The implicated pathways include 
genes found in the Dup7 region, such as GTF2I, ELN 
(the structural protein elastin) and CLIP2 (a cytoplas-
mic linker protein), although no likely damaging vari-
ants were identified in any of the genes within the Dup7 
region, with the exception of CLIP2. Of particular interest 
is the finding that the adaptive behaviour SSs of individu-
als with Dup7 were negatively correlated with a higher 
burden of rare likely damaging missense variants in genes 
expressed in the prenatal human brain. Here, implicated 
variants included a missense variant in CLIP2, and vari-
ants in known ASD-risk genes and/or neuropsychiatric 
Fig. 4 Volcano plot of relationship between CSS and likely damaging variants in GO and neuroset pathways. Volcano plot of low frequency likely 
damaging LoF (5%) in neuroset pathways for the CSS outcome variable. Labelled functions met a P value cut‑off of at most 0.05 and have a false 
discovery rate (FDR) of ≤ 0.15. CSS ADOS‑2 calibrated severity score, GO gene ontology, LoF loss of function
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phenotypes, such as SETD5 (a methyltransferase) and 
CHD2 (a chromodomain helicase DNA-binding protein). 
Similarly, we found that overall intellectual ability SSs 
were negatively correlated with rare likely damaging LoF 
variants in nervous system development and two mem-
brane GO component pathways, where enriched variants 
were present in genes encoding receptors (e.g. CHRNA3, 
AGER) and cell adhesion molecules (e.g. PCDHB9, 
PCDHA8). While some of these enriched variants merit 
further investigation as they are either present in the 
Dup7 region or in genes associated with known disor-
ders, it is important to note that none of these variants 
meet pathogenicity criteria as per ACMG guidelines. 
Functional characterization of these implicated variants 
is necessary to understand how they interact with the 
primary variant (Dup7), other rare and low frequency 
variants in the genetic background, and how they ulti-
mately modulate the Dup7-associated phenotype.
Taken together, our findings point to a model where 
rather than discrete second hits, the complexity of clini-
cal characteristics in Dup7-associated neuropsychiat-
ric phenotypes is modulated by rare and low frequency 
variants, which are present in the genetic background in 
addition to the primary pathogenic Dup7 variant. This 
study highlights the power of pathway analyses and the 
correlation of quantitative traits toward understanding 
how additional rare variants in the genetic background 
modulate neurodevelopmental disorders.
Our results should be interpreted in the context of the 
following limitations. Firstly, we only carried out WGS 
analysis for the Dup7 carriers in this study, and not 
parents, thus the inheritance of the identified variants 
remains unknown. We only examined SNVs and CNVs 
in the Dup7 cohort, and thus cannot rule out that differ-
ences or a burden of other variant types (such as struc-
tural variants) may be able to differentiate between the 
Dup7-ASD and Dup7-non-ASD groups. Finally, it should 
be noted that because this is a small cohort (n = 20), we 
could not evaluate variants with smaller effect sizes, such 
as common variants (i.e. ≥ 5% frequency) and non-coding 
variants, other than those which disrupt splicing. Instead, 
this study can serve as a baseline when evaluating pheno-
typic variability in larger Dup7 cohorts.
To date, there has been no analysis of exome or genome 
data to investigate possible genetic factors in individuals 
with both Dup7 and ASD, making our study the first to 
systematically examine the role of rare and low frequency 
variants in Dup7-ASD. However, exome data have been 
analyzed for individuals with both ASD and WBS [21, 
34]. Codina-Sola et  al. (2019) conducted WES in eight 
individuals with WBS-ASD, where seven (87.5%) of the 
7q11.23 deletions were paternal in origin, and a total of 
five inherited rare variants were identified in ASD-related 
or loss-of-function intolerant genes, as well as one de 
novo LoF variant. In contrast, Masson et al. (2019) iden-
tified no clinically relevant secondary hits in their WBS-
ASD cohort (n = 6), and reported 7q11.23 deletions of 
maternal (n = 4) and paternal (n = 1) origin in individu-
als with WBS-ASD. Across the two studies, there is no 
evidence of an imprinting effect in the WBS-ASD phe-
notype. Similarly, in our cohort, the pattern of CNV 
parent-of-origin was similar for both the Dup7-ASD and 
Dup7-non-ASD groups, providing no evidence of an 
imprinting effect in the Dup7-ASD phenotype.
As mentioned earlier, the phenomenon of incomplete 
penetrance and phenotypic variability has been reported 
in multiple neuropsychiatric phenotypes, suggesting that 
secondary variants may be necessary for ASD manifesta-
tion [15–19, 27]. In our study, we did not identify discrete 
second hits which could explain the development of ASD 
in individuals with Dup7, but instead, similar to Pizzo 
et  al. (2018), we identified correlations between differ-
ent phenotypic measures (such as ASD symptom sever-
ity and intellectual ability) and genetic variants enriched 
in related molecular pathways, suggesting that variants 
present in the genetic background play a critical role in 
phenotypic variability.
Conclusions
Overall, in this study, WGS characterization found that 
in the presence of the same pathogenic Dup7 variant, 
additional genetic variants also have an impact on the 
phenotype. Our findings suggest that neuropsychiatric 
phenotypes associated with particular syndromes are 
subject to modulation by additional genetic variants. 
Thus, assessing the role of rare and low frequency vari-
ants present in the genetic background should improve 
the phenotypic correlation in CNV-associated or mono-
genic disorders.
Methods
Participant cohort
We recruited 24 children with Dup7: 12 individuals with 
Dup7-ASD (case) and 12 individuals with Dup7-non-
ASD (control) who were pairwise matched as closely 
as possible on sex, age and ethnicity (Additional file  1: 
Table S1). The presence of classic Dup7 was confirmed in 
each participant through chromosomal microarray anal-
ysis (CMA) using various commercially available plat-
forms and/or quantitative PCR (qPCR). When possible, 
parents were tested for Dup7, and the parent-of-origin of 
de novo CNVs was determined by the analysis of single-
copy microsatellite markers within the Dup7 region [1]. 
ASD diagnosis was determined using the gold-standard 
diagnostic approach [9]. Each participant with Dup7 was 
clinically evaluated using three standardized measures: 
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the Autism Diagnostic Observation Schedule-2 (ADOS-
2) [35], the Differential Ability Scales-II (DAS-II) [36], 
and the Scales of Independent Behavior-Revised (SIB-R) 
[37] (see Additional file  1: Methods). Additional file  1: 
Table  S1 reports characteristics for each participant, 
including sex, ADOS-2 calibrated severity score (CSS, a 
measure of severity of autism-related symptoms), SIB-R 
Broad Independence standard score (BroadInd SS, a 
measure of adaptive behaviour), and DAS-II General 
Conceptual Ability standard score (GCA, a measure of 
overall intellectual ability similar to IQ) [38]. Individual 
ethnicities, Dup7 CNV origins, age at assessment, and 
the ADOS-2 module administered are not included in 
order to preserve participants’ privacy. Two-sided non-
parametric Mann–Whitney U tests were carried out 
to compare clinical characteristics between the Dup7-
ASD and Dup7-non-ASD groups. All procedures were 
approved by the Research Ethics Boards of the University 
of Toronto and/or the University of Louisville, and writ-
ten informed consent was obtained from the parents or 
legal guardians of all participants.
Whole genome sequencing (WGS)
Genomic DNA was extracted from blood using the 
QIAamp DNA Blood Mini Kit (QIAGEN) and then 
sequenced using the Illumina HiSeq X platform at The 
Centre for Applied Genomics. Reads were aligned to 
the reference genome (build GRCh37/hg19) using the 
Burrows-Wheeler Aligner (v.0.7.12) as a sorted binary 
alignment map (BAM) format [39]. Duplicate reads were 
removed by MarkDuplicates from Picard (v.1.133). Local 
realignment, quality recalibration and removal of dupli-
cate reads were carried out using the Broad Institute’s 
Genome Analysis Toolkit (GATK) (v.3.4-46) for each 
genome. Each variant call format (VCF) file was anno-
tated using a custom pipeline based on ANNOVAR, 
which included annotating effects (such as non-synon-
ymous, nonsense or frameshift variants) and various 
features (e.g. whether the variant occurs in an exonic, 
intronic or intergenic region) [40].
To filter for only high-quality variants, the follow-
ing parameters were applied: (1) autosomal heterozy-
gous variants have a genotype quality (GQ) of ≥ 99, and 
an alternative allele fraction (AAF) ≥ 0.3 and ≤ 0.7; (2) 
homozygous variants and those on chromosome X have 
a GQ ≥ 25 and an AAF > 0.7; and (3) all variants passed 
GATK pipeline filters. CNVs were detected using a com-
bination of the ERDS and CNVnator read depth based 
algorithms as previously described [41]. In addition, the 
SpliceAI tool was used to detect non-coding genetic vari-
ants which cause cryptic splicing [28]. To filter for only 
high-quality variants, the following parameters were 
applied: (1) at least one of the SpliceAI delta scores (i.e. 
acceptor or donor gain/loss) ≥ 0.8; and (2) variants which 
impacted inter-genic regions were excluded.
Ancestry and Kinship analyses
Ancestry analyses were conducted using the ancestry 
estimating program ADMIXTURE (v.1.3) and PLINK 
(v.1.9), where samples from the 1000 Genome Project 
were used as reference population groups to gener-
ate estimated ancestry fractions for each Dup7 carrier 
(see Additional file  1: Methods) [42]. Through principal 
component analysis, scatterplots with the top princi-
pal components were generated to observe the ancestry 
clustering pattern of Dup7 carriers. In addition, using 
PLINK-genome, kinship analysis was carried out to gen-
erate estimated identity-by-descent (IBD) proportions 
to determine the degree of relatedness among the Dup7 
carriers.
Rare variant analysis
A rare variant was defined as one which is present in ≤ 1% 
of the population in the following databases: the 1000 
Genomes project, the Exome Aggregation Consortium, 
and the Genome Aggregation Database. This includes 
both missense (non-synonymous) and loss-of-function 
(LoF) variants, where the latter include frameshift inser-
tions or deletions (indels), nonsense and core splice-site 
variants. Rare variants in both the coding and non-cod-
ing region were prioritized using annotation features 
such as sequence conservation, biological relevance, 
probability of LoF intolerance (pLI) scores, genetic mode 
of inheritance, and their predicted impact on coding and 
non-coding sequence using in silico algorithms, specifi-
cally CADD, SIFT, PolyPhen, Provean, MutationAssessor, 
MutationTaster, PhyloPMam, and PhyloPVert. Missense 
variants with high predicted scores in at least four out of 
eight in silico algorithms were considered likely damag-
ing [24, 26].
As per the ACMG interpretation guidelines, rare CNVs 
(as called by ERDS and CNVnator from WGS output) 
were filtered based on their genomic content, and over-
lap with CNVs reported in databases such as DECIPHER 
and the Database of Genomic Variants [43, 44]. Rare 
CNVs were prioritized using various annotation features, 
including whether the CNV (i) impacted protein coding 
regions or functionally important elements, (ii) if there 
was a complete or partial overlap of an established hap-
loinsufficiency genomic region, or (iii) if the reported 
phenotype was highly specific or consistent with the 
impacted region, when compared to the literature and/or 
public databases.
Prioritized rare variants were then classified, as per 
ACMG guidelines, into the following categories: patho-
genic, likely pathogenic, variant of unknown significance 
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(VUS), benign and likely benign [43, 45–47]. Read align-
ments for variants of interest were manually inspected 
using Integrative Genomics Viewer. Variants with a 
high likelihood of disrupting splicing, as predicted by 
SpliceAI, were not included in this rare variant analysis, 
as the interpretation guidelines established by the Ameri-
can College of Medical Genetics and Genomics (ACMG) 
are restricted to the evaluation of genetic variants in 
canonical ± 1 or 2 splice sites.
Genomic variant burden analysis
The burden of genomic variants was analyzed using the 
following regression models in R:
logit(binary outcome variable) = sex + age + burden 
variable.
continuous outcome variable = sex + age + burden 
variable.
In each model, the number of qualifying variants per 
sample at varying frequency levels (either rare [≤ 1%] or 
low frequency [< 5%]) were defined as the burden vari-
able to test—which included testing (1) LoF SNVs; (2) 
missense SNVs; and (3) non-Dup7 CNVs impacting 
both the coding and non-coding regions of the genome. 
In the case of missense SNVs, all eight prediction algo-
rithms were tested sequentially i.e. mis_1 refers to one of 
the eight algorithms supporting that a missense variant 
was likely damaging, mis_2 refers to two supporting algo-
rithms, etc.
Both binary (i.e. Dup7-ASD or Dup7-non-ASD) and 
continuous (SIB-R and DAS-II SSs) phenotypic meas-
ures were used as outcome variables to construct mod-
els for correlation studies. Each model also included the 
participant’s sex and age as covariates for potential con-
founding effects. Control models were constructed using 
synonymous variants and non-frameshift indels to see 
the potential effect of other confounders. The false dis-
covery rate (FDR) was calculated to account for multiple 
comparisons.
For each burden analysis, the target variable had to 
meet the following thresholds to reach significance: (1) 
the B (raw coefficient) was positive for models using 
Dup7-ASD/Dup7-non-ASD or CSS as an outcome vari-
able and negative for models using GCA and BroadInd 
SS as an outcome variable; (2) met a P value cut-off of at 
most 0.05; and (3) had an FDR value ≤ 0.15. One-tailed 
statistics are reported, and corresponding volcano plots 
were generated for each model where the target variable 
met significance.
Function and pathway enrichment analyses
Similar to the above burden analyses, function and 
pathway enrichment analyses on gene-sets with rare 
and low frequency variants were carried out on the 
Dup7 cohort using regression models in R. Here, we 
correlated the results with categorical and quantitative 
phenotypic measures (i.e. Dup7-ASD or Dup7-non-
ASD, or SIB-R and DAS-II SSs). We tested the follow-
ing burden variables: (1) LoF SNVs; (2) likely damaging 
missense SNVs (as defined above i.e. at least four out of 
eight in silico algorithms supported the variant’s likely 
damaging effect); and (3) non-Dup7 CNVs. Two differ-
ent gene-sets were used: (1) a combination of an ASD-
related gene list (consisting of 1132 genes that have 
been reported to have an association with ASD) and 51 
neuro-related gene-sets i.e., Neuroset (which were col-
lected based on their neural function, brain expression 
or neural disease phenotypes); and (2) two commonly 
used gene pathway systems: Geno Ontology (GO) 
and the Kyoto Encyclopedia of Genes and Genomes 
(KEGG), where the gene-set size was limited to 100–
1000 genes [24, 26, 48].
The function and pathway analyses were also repeated 
to include non-coding genetic variants with a high like-
lihood of disrupting splicing, as predicted by SpliceAI, 
in the LoF SNV burden variable (1%, 5%).
Supplementary Information
The online version contains supplementary material available at https ://doi.
org/10.1186/s1302 3‑020‑01648 ‑6.
Additional file 1. Supplementary Materials and Methods.
Abbreviations
AAF: Alternative allele fraction; ACMG: American College of Medical Genetics 
and Genomics; ADOS‑2: Autism Diagnostic Observation Schedule‑2; ASD: 
Autism spectrum disorder; BroadInd SS: SIB‑R Broad Independence standard 
score; CMA: Chromosomal microarray analysis; CNV: Copy number variant; 
CSS: Calibrated severity score; DAS‑II: Differential Ability Scales‑II; DEL: Dele‑
tion; Dup7: Duplication of the 7q11.23 region; FDR: False discovery rate; GATK: 
Genome analysis toolkit; GCA : DAS‑II General Conceptual Ability standard 
score; GO: Geno ontology; GQ: Genotype quality; IBD: Identity‑by‑descent; 
Indel: Insertion or deletion; KEGG: Kyoto Encyclopedia of Genes and Genomes; 
LoF: Loss‑of‑function; NDD: Neurodevelopmental disorder; P: P Value; PC: Prin‑
cipal component; pLI: Probability of LoF intolerance; qPCR: Quantitative poly‑
merase chain reaction; SIB‑R: Scales of Independent Behavior‑Revised; SNV: 
Single nucleotide variant; VCF: Variant call format; VUS: Variant of uncertain 
significance; WBS: Williams‑Beuren Syndrome; WES: Whole‑exome sequencing; 
WGS: Whole‑genome sequencing; 22q11DS: 22Q11 deletion syndrome.
Acknowledgements
The authors would like to thank the children with Dup7 and their families for 
their participation in this study. We would also like to thank the members of 
the University of Louisville Neurodevelopmental Sciences Lab for data col‑
lection, and members of The Centre for Applied Genomics (TCAG), especially 
Bhooma Thiruvahindrapuram and Wilson Sung, for their help in processing 
genome data.
Authors’ contributions
LRO and RKCY designed the study. BPKT and CBM performed or supervised 
the psychological assessments. ET, LRO, and CAM performed molecular char‑
acterization of 7q11.23 duplications. FQ, RKCY and YY performed the statistical 
analyses, with critical review from CBM. FQ and RKCY wrote the manuscript. All 
authors read and approved the final manuscript.
Page 10 of 11Qaiser et al. Orphanet J Rare Dis            (2021) 16:6 
Funding
This work was supported by grants from the University of Toronto McLaughlin 
Centre to LRO and RKCY, a Nancy E.T. Fahrner Award and a SickKids Catalyst 
Scholar in Genetics to RKCY, the Canadian Institutes of Health Research 
(MOP77720) to LRO, and the Simons Foundation Autism Research Initiative 
(SFARI 238896), the National Institute of Neurological Disorders and Stroke 
(R01 NS35102), and the National Institute of Child Health and Development 
(R37 HD29957) to CBM.
Availability of data and materials
The dataset(s) supporting the conclusions of this article is(are) included within 
the article (and its supplementary information files). Individual ethnicities, 
Dup7 CNV origins, age at assessment, and the ADOS‑2 module administered 
are not included in order to preserve participants’ privacy.
Ethics approval
All procedures were approved by the Research Ethics Board of the University 
of Toronto and/or the Institutional Review Board of the University of Louisville.
Consent to participate and for publication
Written informed consent was obtained from the parents or legal guardians of 
all participants, and participants provided oral or written assent.
Competing Interests
The authors declare that they have no competing interests.
Author details
1 Department of Molecular Genetics, University of Toronto, Toronto, ON, 
Canada. 2 Genetics & Genome Biology Program, The Hospital for Sick Children, 
686 Bay St., Toronto, ON M5G 0A4, Canada. 3 Department of Psychological 
and Brain Sciences, University of Louisville, Louisville, KY, USA. 4 Department 
of Pediatrics, UNLV School of Medicine, Las Vegas, NV, USA. 5 Department 
of Psychology, University of Wisconsin‑Milwaukee, Milwaukee, WI, USA. 
6 Department of Medicine, University of Toronto, Toronto, ON, Canada. 
Received: 23 June 2020   Accepted: 14 December 2020
References
 1. Somerville MJ, Mervis CB, Young EJ, Seo E‑J, del Campo M, Bamforth S, 
et al. Severe expressive‑language delay related to duplication of the Wil‑
liams–Beuren locus. N Engl J Med. 2005;353(16):1694–701.
 2. Van der Aa N, Rooms L, Vandeweyer G, van den Ende J, Reyniers E, 
Fichera M, et al. Fourteen new cases contribute to the characteriza‑
tion of the 7q11.23 microduplication syndrome. Eur J Med Genet. 
2009;52(2–3):94–100.
 3. Velleman SL, Mervis CB. Children with 7q11.23 duplication syndrome: 
speech, language, cognitive, and behavioral characteristics and their 
implications for intervention. Perspect Lang Learn Educ. 2011;18(3):108.
 4. Mervis CB, Klein‑Tasman BP, Huffman MJ, Velleman SL, Pitts CH, Hender‑
son DR, et al. Children with 7q11.23 duplication syndrome: psychological 
characteristics. Am J Med Genet A. 2015;167A:1436–50.
 5. Morris CA, Mervis CB, Paciorkowski AP, Abdul‑Rahman O, Dugan SL, Rope 
AF, et al. 7q11.23 duplication syndrome: physical characteristics and 
natural history. Am J Med Genet A. 2015;167(12):2916–35.
 6. Merla G, Brunetti‑Pierri N, Micale L, Fusco C. Copy number variants at Wil‑
liams–Beuren syndrome 7q11.23 region. Hum Genet. 2010;128(1):3–26.
 7. Sanders SJ, Ercan‑Sencicek AG, Hus V, Luo R, Murtha MT, Moreno‑De‑Luca 
D, et al. Multiple recurrent de novo CNVs, including duplications of the 
7q11.23 Williams syndrome region, are strongly associated with autism. 
Neuron. 2011;70:863–85.
 8. Levy D, Ronemus M, Yamrom B, Lee Y, Leotta A, Kendall J, et al. Rare de 
novo and transmitted copy‑number variation in autistic spectrum disor‑
ders. Neuron. 2011;70:886–97.
 9. Klein‑Tasman BP, Mervis CB. Autism spectrum symptomatology among 
children with Duplication 7q11.23 syndrome. J Autism Dev Disord. 
2018;48(6):1982–94.
 10. Berg JS, Brunetti‑Pierri N, Peters SU, Kang SHL, Fong CT, Salamone J, et al. 
Speech delay and autism spectrum behaviors are frequently associated 
with duplication of the 7q11.23 Williams–Beuren syndrome region. Genet 
Med. 2007;9(7):427–41.
 11. Malenfant P, Liu X, Hudson ML, Qiao Y, Hrynchak M, Riendeau 
N, et al. Association of GTF2i in the Williams–Beuren Syndrome 
critical region with autism spectrum disorders. J Autism Dev Disord. 
2012;42(7):1459–69.
 12. Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. 
Curr Opin Genet Dev. 2012;22(3):229–37.
 13. Klein‑tasman BP, van der Fluit F, Mervis CB. Autism spectrum symptoma‑
tology in children with Williams syndrome who have phrase speech or 
fluent language. J Autism Dev Disord. 2019;48(9):3037–50.
 14. Becerra AM, Mervis CB. Age at onset of declarative gestures and 
24‑month expressive vocabulary predict later language and intellec‑
tual abilities in young children with Williams syndrome. Front Psychol. 
2019;10:2648.
 15. Hammer MF, Ishii A, Johnstone L, Tchourbanov A, Lau B, Sprissler R, et al. 
Rare variants of small effect size in neuronal excitability genes influence 
clinical outcome in Japanese cases of SCN1A truncation‑positive Dravet 
syndrome. PLoS ONE. 2017;12(7):1–16.
 16. Pizzo L, Jensen M, Polyak A, Rosenfeld JA, Mannik K, Krishnan A, et al. Rare 
variants in the genetic background modulate cognitive and develop‑
mental phenotypes in individuals carrying disease‑associated variants. 
Genet Med. 2018;21:816–25.
 17. Wenger TL, Kao C, McDonald‑Mcginn DM, Zackai EH, Bailey A, Schultz 
RT, et al. The role of mGluR copy number variation in genetic and 
environmental forms of syndromic autism spectrum disorder. Sci Rep. 
2016;6:19372.
 18. Karaca E, Posey JE, Coban Akdemir Z, Pehlivan D, Harel T, Jhangiani SN, 
et al. Phenotypic expansion illuminates multilocus pathogenic variation. 
Genet Med. 2018;20(12):1528–37.
 19. D’Angelo D, Lebon S, Chen Q, Martin‑Brevet S, Snyder LG, Hippolyte L, 
et al. Defining the effect of the 16p11.2 duplication on cognition, behav‑
ior, and medical comorbidities. JAMA Psychiatry. 2016;73(1):20–30.
 20. Schaaf CP, Sabo A, Sakai Y, Crosby J, Muzny D, Hawes A, et al. Oligogenic 
heterozygosity in individuals with high‑functioning autism spectrum 
disorders. Hum Mol Genet. 2011;20(17):3366–75.
 21. Masson J, Demily C, Chatron N, Labalme A, Schluth‑bolard C, Gilbert‑dus‑
sardier B, et al. Molecular investigation, using chromosomal microarray 
and whole exome sequencing, of six patients affected by Williams–
Beuren syndrome and autism spectrum disorder. Orphanet J Rare Dis. 
2019;5:1–6.
 22. Jiang Y, Yuen RKC, Jin X, Wang M, Chen N, Wu X, et al. Detection of clini‑
cally relevant genetic variants in autism spectrum disorder by whole‑
genome sequencing. Am J Hum Genet. 2013;93:249–63.
 23. Tammimies K, Fernandez BA, Walker S, Thiruvahindrapuram B, Kaur G, 
Lionel AC, et al. High resolution genomic analyses of a clinically defined 
autism spectrum disorder cohort. Int J Dev Neurosci. 2015;47A:76.
 24. Yuen RKC, Thiruvahindrapuram B, Merico D, Walker S, Tammimies K, 
Hoang N, et al. Whole‑genome sequencing of quartet families with 
autism spectrum disorder. Nat Med. 2015;21(2):185–91.
 25. Stavropoulos DJ, Merico D, Jobling R, Bowdin S, Monfared N, Thiruvahin‑
drapuram B, et al. Whole‑genome sequencing expands diagnostic utility 
and improves clinical management in paediatric medicine. npj Genomic 
Med. 2016;1:15012.
 26. Yuen RK, Merico D, Cao H, Pellecchia G, Alipanahi B, Thiruvahindrapuram 
B, et al. Genome‑wide characteristics of de novo mutations in autism. npj 
Genomic Med. 2016;1(1):16027.
 27. Bijlsma EK, Gijsbers ACJ, Schuurs‑Hoeijmakers JHM, van Haeringen A, 
Fransen van de Putte DE, Anderlid BM, et al. Extending the phenotype 
of recurrent rearrangements of 16p11.2: deletions in mentally retarded 
patients without autism and in normal individuals. Eur J Med Genet. 
2009;52(2–3):77–87.
 28. Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, 
Knowles D, Li YI, et al. Predicting splicing from primary sequence with 
deep learning. Cell. 2019;176(3):535–48.
 29. Mefford H, Sharp A, Baker C, Itsara A, Jiang Z, Buysse K, et al. Recurrent 
rearrangements of chromosome 1q21.1 and variable pediatric pheno‑
types. N Engl J Med. 2008;359(16):1685–99.
 30. Bernier R, Steinman KJ, Reilly B, Wallace AS, Sherr EH, Pojman N, et al. 
Clinical phenotype of the recurrent 1q21.1 copy‑number variant. Genet 
Med. 2016;18(4):341–9.
Page 11 of 11Qaiser et al. Orphanet J Rare Dis            (2021) 16:6  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 31. Petek E, Schwarzbraun T, Noor A, Patel M, Nakabayashi K, Choufani S, et al. 
Molecular and genomic studies of IMMP2L and mutation screening in 
autism and Tourette syndrome. Mol Genet Genomics. 2007;277(1):71–81.
 32. Petek E, Windpassinger C, Vincent JB, Cheung J, Boright AP, Scherer SW, 
et al. Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31 associ‑
ated with Tourette syndrome. Am J Hum Genet. 2001;68:848–58.
 33. Zhang Y, Liu Y, Zarrei M, Tong W, Dong R, Wang Y, et al. Association of 
IMMP2L deletions with autism spectrum disorder: a trio family study 
and meta‑analysis. Am J Med Genet Part B Neuropsychiatr Genet. 
2018;177(1):93–100.
 34. Codina‑Sola M, Costa‑Roger M, Pérez‑García D, Flores R, Palacios‑Verdú 
MG, Cusco I, et al. Genetic factors contributing to autism spectrum disor‑
der in Williams–Beuren syndrome. J Med Genet. 2019;56:801–8.
 35. Lord C, Rutter M, DiLavore P, Risi S, Gotham K, Bishop S. Autism Diagnostic 
Observation Schedule. 2nd ed. Los Angeles, CA: Western Psychological 
Services; 2012.
 36. Elliott C. Differential Ability Scales. 2nd ed. San Antonio, TX: Psychological 
Corporation; 2007.
 37. Bruininks R, Woodcock R, Weatherman R, Hill B. Scales of Independent 
Behaviour—Revised. Chicago, IL: Riverside; 1996.
 38. Gotham K, Pickles A, Lord C. Standardizing ADOS scores for a meas‑
ure of severity in autism spectrum disorders. J Autism Dev Disord. 
2009;39(5):693–705.
 39. Li H, Durbin R. Fast and accurate long‑read alignment with Burrows–
Wheeler transform. Bioinformatics. 2010;26(5):589–95.
 40. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic 
variants from high‑throughput sequencing data. Nucleic Acids Res. 
2010;38(16):1–7.
 41. Trost B, Walker S, Wang Z, Thiruvahindrapuram B, MacDonald JR, Sung 
WWL, et al. A comprehensive workflow for read depth‑based identifica‑
tion of copy‑number variation from whole‑genome sequence data. Am J 
Hum Genet. 2018;102:142–55.
 42. Roslin NM, Li W, Paterson AD, Strug LJ. Quality control analysis of the 1000 
Genomes Project Omni2.5 genotypes. bioRxiv. 2016;
 43. Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. 
Technical standards for the interpretation and reporting of constitutional 
copy‑number variants: a joint consensus recommendation of the Ameri‑
can College of Medical Genetics and Genomics (ACMG) and the Clinical 
Genome Resource (ClinGen). Genet Med. 2019;1–13.
 44. South ST, Lee C, Lamb AN, Higgins AW, Kearney HM. ACMG Standards 
and Guidelines for constitutional cytogenomic microarray analysis, 
including postnatal and prenatal applications: revision 2013. Genet Med. 
2013;
 45. Abou Tayoun AN, Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, 
et al. Recommendations for interpreting the loss of function PVS1 ACMG/
AMP variant criterion. Hum Mutat. 2018;39(11):1517–24.
 46. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier‑Foster J, et al. Standards 
and guidelines for the interpretation of sequence variants: a joint con‑
sensus recommendation of the American College of Medical Genetics 
and Genomics and the Association for Molecular Pathology. Genet Med. 
2015;17(5):405–24.
 47. Kearney HM, Thorland EC, Brown KK, Quintero‑Rivera F, South ST. Ameri‑
can College of Medical Genetics standards and guidelines for interpreta‑
tion and reporting of postnatal constitutional copy number variants. 
Genet Med. 2011;13(7):680–5.
 48. Trost B, Engchuan W, Nguyen CM, Thiruvahindrapuram B, Dolzhenko E, 
Backstrom I, et al. Genome‑wide detection of tandem DNA repeats that 
are expanded in autism. Nature. 2020;586(7827):80–6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
